-

09:44:19 AM

EYEN Stock News

EYEN - Eyenovia Inc

06/06/23 9:00 AM

Nasdaq : EYEN

Eyenovia Expands Its US Manufacturing Capabilities

Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, CaliforniaNEW YORK, NY / ACCESSWIRE / June 6, 2023 / Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company commercializing and

RHEA-AI

very positive

06/01/23 8:00 AM

Nasdaq : EYEN

Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023

Presentation to highlight recent FDA approval of Mydcombi™ for mydriasis which leverages Eyenovia’s novel Optejet dispensing device Optejet represents the first true advancement in the topical administration of ophthalmic medications in more than 100 years NEW YORK, June 01, 2023

RHEA-AI

neutral

05/11/23 4:05 PM

Nasdaq : EYEN

earnings

Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update

Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet ® Received feedback from FDA on its Phase 3 Microline presbyopia candidate that provides a clear and efficient path forward for the

RHEA-AI

positive

05/08/23 8:00 AM

Nasdaq : EYEN

fda approval

Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform

RHEA-AI

neutral

05/04/23 8:00 AM

Nasdaq : EYEN

conferencesearnings

Eyenovia to Report First Quarter 2023 Results on Thursday, May 11

Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic

RHEA-AI

neutral

04/24/23 8:00 AM

Nasdaq : EYEN

Eyenovia Announces Poster Presentation at ARVO 2023

Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as

RHEA-AI

neutral

03/30/23 4:05 PM

Nasdaq : EYEN

earnings

Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update

Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining a clear path forward for the program Entered into

RHEA-AI

positive

03/23/23 8:00 AM

Nasdaq : EYEN

conferences

Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30

Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in combination with its own drug-device

RHEA-AI

neutral

02/28/23 4:05 PM

Nasdaq : EYEN

Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement

Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as

RHEA-AI

neutral

02/15/23 3:00 AM

Nasdaq : EYEN

Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

Taiwan- based Formosa Pharmaceuticals announced today that the company has entered into a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutics. The foundation of the collaboration lies in the combination of Formosa's APNT™ formulation platform with Eyenovia's Optejet ® delivery system.

RHEA-AI

positive

1 2 3 4 5 6 7 8 9 Next